Researchers at Cold Spring Harbor Laboratory have created a list of genetic “usual suspects” from a computational analysis of 635 datasets across around 27,000 genetic samples.
Data is at the heart of applicable genomics. As the volume and depth of genomic data grows, bioinformaticians are translating the data into interpretable patterns leading to new biological insight.
D4: Pharma is a highly-select gathering of 80-100 very senior and experienced pharma professionals responsible for making important decisions, as well as turning innovation and new ideas into measurable progress.
With so many talks and panels occurring across our four stages and Live Lounge, we understand that it can be pretty hard to pick out the most unmissable discussions at the festival this year. Given the conundrum, we thought we’d help out! We’ve selected a couple of talks and panels occurring across the two days which we think will be incredibly interesting and enormously informative for a whole range of people.
With both our own festival and the wider life sciences sector moving rapidly towards a more integrative and holistic treatment of different -omics in research and drug development, we thought we’d get Dr. Dennis Wang, Lecturer in Bioinformatics and Genomics Medicine at the NIHR Sheffield Biomedical Research Centre, to talk us through the shift towards multi-omics.
Data integration has been one of the major trends of the last few years, and one which will become ever-more important as the life sciences sectors progress further. Dr. Maya Ghoussaini, Genetic Analysis Team Leader at the Wellcome Sanger Institute, and Dr. Denise Carvalho-Silva, Scientific Outreach Lead at EMBL-EBI, both working at Open Targets, here discuss the importance of this process, and their own work within the realm of data integration.
We know it’s hard to believe, but right now there are still some people who haven’t made up their minds to come to the 2019 Festival. Lucky for them we plan for every eventuality, and have prepared the five main reasons everyone should be registering their place at the event right now.
A Boston biotechnology company has built a neural network which examines the overall elements of the human face and compiles a list of the ten genetic syndromes that person potentially has, possibly helping medical professionals narrow down the diagnosis for that individual.
The first results of the BabySeq Project, a study to determine whether deep dives into infant DNA could uncover more diseases, and whether making this procedure routine after childbirth would be worth it, have been published.
A new AI program can predict the symptoms of a patient’s cancer and their severity of the course of treatment.
Data compression startup PetaGene has closed a significant contract with biopharma company Romulus Capital, attracting £2.1 million in funding from that organisation and several other investors based in Silicon Valley and London. This investment round brings PetaGene’s total funding to $3.2 million.
Time to pop the champagne – 100,000 genomes have been reached. Well done Genomics England!
Gene discovery could help pave way for development treatment for hearing loss
Single nucleotide variations could be the key to better identification of tumour subpopulations
Consumers can contribute to medical breakthroughs and get rewarded for sharing health and genomic data while maintaining privacy and control.
Dr. Jonathan Rothberg is a man who needs little introduction, and is now receiving the Association of Molecular Pathology’s (AMP) Award for Excellence in Molecular Diagnostics Services. We spoke to him about his many achievements, his proudest moments, and the future of his fascinating field.